

**TOXICOLOGICAL PROFILE FOR
TOLUENE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 2000

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Jeffrey P. Koplan, M.D., M.P.H.

Administrator

Agency for Toxic Substances and
Disease Registry

*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on October 21, 1999 (64 FR 56792). For prior versions of the list of substances, see *Federal Register* notices dated April 17, 1987 (52 FR 12866); October 20, 1988(53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); and November 17, 1997 (62 FR 61332). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Health Effects: Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can Toluene Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to Toluene?
Section 2.7	Children's Susceptibility
Section 5.6	Exposures of Children

Other Sections of Interest:

Section 2.8	Biomarkers of Exposure and Effect
Section 2.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 639-6357 **Fax:** (404) 639-6359
E-mail: atsdric@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: aoec@dgs.dgsys.com • AOEC Clinic Director: <http://occ-env-med.mc.duke.edu/oem/aoec.htm>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Alfred Dorsey, D.V.M.
ATSDR, Division of Toxicology, Atlanta, GA

Peter R. McClure, Ph.D., D.A.B.T.
Syracuse Research Corporation, North Syracuse, NY

A. Rosa McDonald, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

Mona Singh, Ph.D.
Syracuse Research Corporation, Arlington, VA

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for Toluene. The panel consisted of the following members:

1. Dr. Clint Skinner, Skinner Associates, 3985 Shooting Star Road, Creston, CA 93432; and
2. Dr. Robert G. Tardiff, 1423 Trapline Court, Vienna, VA 22189.

These experts collectively have knowledge of Toluene's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xviii
LIST OF TABLES	xx
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS TOLUENE?	1
1.2 WHAT HAPPENS TO TOLUENE WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO TOLUENE?	3
1.4 HOW CAN TOLUENE ENTER AND LEAVE MY BODY?	4
1.5 HOW CAN TOLUENE AFFECT MY HEALTH?	4
1.6 HOW CAN TOLUENE AFFECT CHILDREN?	6
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO TOLUENE?	8
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO TOLUENE?	8
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	9
1.10 WHERE CAN I GET MORE INFORMATION?	10
2. HEALTH EFFECTS	11
2.1 INTRODUCTION	11
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	11
2.2.1 Inhalation Exposure	12
2.2.1.1 Death	12
2.2.1.2 Systemic Effects	13
2.2.1.3 Immunological and Lymphoreticular Effects	55
2.2.1.4 Neurological Effects	57
2.2.1.5 Reproductive Effects	70
2.2.1.6 Developmental Effects	72
2.2.1.7 Genotoxic Effects	75
2.2.1.8 Cancer	76
2.2.2 Oral Exposure	78
2.2.2.1 Death	79
2.2.2.2 Systemic Effects	79
2.2.2.3 Immunological and Lymphoreticular Effects	92
2.2.2.4 Neurological Effects	93
2.2.2.5 Reproductive Effects	94
2.2.2.6 Developmental Effects	94
2.2.2.7 Genotoxic Effects	95

2.2.2.8	Cancer	95
2.2.3	Dermal Exposure	96
2.2.3.1	Death	96
2.2.3.2	Systemic Effects	96
2.2.3.3	Immunological and Lymphoreticular Effects	98
2.2.3.4	Neurological Effects	98
2.2.3.5	Reproductive Effects	98
2.2.3.6	Developmental Effects	98
2.2.3.7	Genotoxic Effects	98
2.2.3.8	Cancer	99
2.3	TOXICOKINETICS	99
2.3.1	Absorption	100
2.3.1.1	Inhalation Exposure	100
2.3.1.2	Oral Exposure	100
2.3.1.3	Dermal Exposure	101
2.3.2	Distribution	102
2.3.2.1	Inhalation Exposure	102
2.3.2.2	Oral Exposure	105
2.3.2.3	Dermal Exposure	105
2.3.3	Metabolism	106
2.3.4	Elimination and Excretion	110
2.3.4.1	Inhalation Exposure	110
2.3.4.2	Oral Exposure	112
2.3.4.3	Dermal Exposure	113
2.3.5	Physiologically based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	113
2.4	MECHANISMS OF ACTION	119
2.4.1	Pharmacokinetic Mechanisms	119
2.4.2	Mechanisms of Toxicity	120
2.4.3	Animal-to-Human Extrapolations	124
2.5	RELEVANCE TO PUBLIC HEALTH	125
2.6	ENDOCRINE DISRUPTION	138
2.7	CHILDREN'S SUSCEPTIBILITY	142
2.8	BIOMARKERS OF EXPOSURE AND EFFECT	147
2.8.1	Biomarkers Used to Identify or Quantify Exposure to Toluene	148
2.8.2	Biomarkers Used to Characterize Effects Caused by Toluene	149
2.9	INTERACTIONS WITH OTHER CHEMICALS	149
2.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	153
2.11	METHODS FOR REDUCING TOXIC EFFECTS	154
2.11.1	Reducing Peak Absorption Following Exposure	154
2.11.2	Reducing Body Burden	155
2.11.3	Interfering with the Mechanism of Action for Toxic Effects	155
2.12	ADEQUACY OF THE DATABASE	156
2.12.1	Existing Information on Health Effects of Toluene	156
2.12.2	Identification of Data Needs	158
2.12.3	Ongoing Studies	166
3.	CHEMICAL AND PHYSICAL INFORMATION	169
3.1	CHEMICAL IDENTITY	169
3.2	PHYSICAL AND CHEMICAL PROPERTIES	169

4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	173
4.1 PRODUCTION	173
4.2 IMPORT/EXPORT	176
4.3 USE	176
4.4 DISPOSAL	176
5. POTENTIAL FOR HUMAN EXPOSURE	179
5.1 OVERVIEW	179
5.2 RELEASES TO THE ENVIRONMENT	180
5.2.1 Air	185
5.2.2 Water	185
5.2.3 Soil	186
5.3 ENVIRONMENTAL FATE	186
5.3.1 Transport and Partitioning	186
5.3.2 Transformation and Degradation	188
5.3.2.1 Air	188
5.3.2.2 Water	188
5.3.2.3 Sediment and Soil	189
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	190
5.4.1 Air	190
5.4.2 Water	193
5.4.3 Sediment and Soil	194
5.4.4 Other Environmental Media	194
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	194
5.6 EXPOSURES OF CHILDREN	198
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	200
5.8 ADEQUACY OF THE DATABASE	201
5.8.1 Identification of Data Needs	201
5.8.2 Ongoing Studies	205
6. ANALYTICAL METHODS	207
6.1 BIOLOGICAL SAMPLES	207
6.2 ENVIRONMENTAL SAMPLES	210
6.3 ADEQUACY OF THE DATABASE	216
6.3.1 Identification of Data Needs	217
6.3.2 Ongoing Studies	218
7. REGULATIONS AND ADVISORIES	219
8. REFERENCES	229
9. GLOSSARY	307
APPENDICES	
C. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
D. USER'S GUIDE	B-1
E. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1

LIST OF FIGURES

2-1	Levels of Significant Exposure to Toluene - Inhalation	38
2-2	Levels of Significant Exposure to Toluene - Oral	87
2-3	Scheme for Toluene Metabolism in Humans and Animals	107
2-4	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	115
2-5	Existing Information on Health Effects of Toluene	157
5-1	Frequency of NPL Sites with Toluene Contamination	181

LIST OF TABLES

2-1	Levels of Significant Exposure to Toluene - Inhalation	14
2-2	Levels of Significant Exposure to Toluene - Oral	80
2-3	Levels of Significant Exposure to Toluene - Dermal	97
2-4	Genotoxicity of Toluene <i>In Vivo</i>	139
2-5	Genotoxicity of Toluene <i>In Vitro</i>	140
2-6	Ongoing Research for Toluene	167
3-1	Chemical Identity of Toluene	170
3-2	Physical and Chemical Properties of Toluene	171
4-1	Facilities that Manufacture or Process Toluene	174
5-1	Releases to the Environment from Facilities that Manufacture or Process Toluene	182
5-2	Median Toluene Levels in Ambient Air	191
5-3	Ongoing Studies on the Potential for Human Exposure to Toluene	206
6-1	Analytical Methods for Determining Toluene in Biological Materials	208
6-2	Analytical Methods for Determining Biomarkers of Toluene in Biological Samples	211
6-3	Analytical Methods for Determining Toluene in Environmental Samples	212
7-1	Regulations and Guidelines Applicable to Toluene	222